Vaccitech to Participate at The 33rd Annual Virtual Piper Sandler Healthcare Conference
- Stocks tumble on new coronavirus variant fear
- Moderna (MRNA) Shares Rally 11% on 'Nu' Concerns, Analyst Sees mRNA Technology Adapting Much Quicker to New COVID Variant
- DiDi (DIDI) Stock Falls on Report China Seeks Delisting From US Amid Data Security Concerns
- Apple (AAPL) on Pace to Sell Over 10 Million iPhones for Black Friday - Wedbush
- Buy Tech Winners on Variant Fears - Wedbush
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
OXFORD, United Kingdom, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that Bill Enright, Chief Executive Officer, and Georgy Egorov, Chief Financial Officer, are participating at the 33rd Annual Virtual Piper Sandler Healthcare Conference November 30th to December 2nd, 2021. A pre-recorded fireside chat with Bill Enright and Georgy Egorov is available at the link below.
|Event:||33rd Piper Sandler Annual Healthcare Conference|
|Fireside Chat:||Virtual on-demand webcast|
|Time/date:||10 a.m. EST, Nov. 22 and available for approximately 90 days|
|Webcast:||Events section of the Vaccitech website|
About Vaccitech plcVaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company’s proprietary platform comprises proprietary modified simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, as well as the well-validated Modified Vaccinia Ankara, or MVA, boost vector, both with demonstrable tolerability profiles and without the ability to replicate in humans. The combination of a ChAdOx prime treatment with subsequent MVA boost has consistently generated significantly higher magnitudes of CD8+ T cells compared with other technologies and approaches. The company has a broad pipeline of both clinical and preclinical stage therapeutic programs in solid tumors and viral infections and prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of the milestones and royalty income received by OUI from AstraZeneca.
Vaccitech Media contacts:Katja Stout, Scius Communications (EU)Direct: +44 (0) 7789435990Email: firstname.lastname@example.orgRobert Flamm, Ph.D. 212-213-0006 ext. 364Email: email@example.com Henry Hodge, VaccitechEmail: firstname.lastname@example.org
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Black Friday & Cyber Monday Apple Watch Deals 2021: Apple Watch Series 7, SE, 6, 5, 4 & More Sales Researched by Consumer Walk
- Solis Announces Investor Presentation
- Best Black Friday & Cyber Monday Samsung Galaxy S21 Deals (2021): Top Galaxy S21 Ultra 5G, S21+ & S21 Deals Reviewed by Spending Lab
Create E-mail Alert Related CategoriesGlobe Newswire, Press Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!